Abvc biopharma abv-1505 adhd phase iia results presented at 2023 apsard conference

Fremont, ca, jan. 19, 2023 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that dr. keith mcburnett, professor of psychiatry at the university of california san francisco, presented the results of the phase iia study of its medical treatment, abv-1505 adhd, on january 14, 2023 at the 2023 conference of the american professional society of adhd and related disorders (apsard) poster session. apsard is a world-renowned organization consisting of a broad spectrum of allied mental health experts working to improve the quality of care for patients with adhd through the advancement and dissemination of research, and evidence-based practices.
ABVC Ratings Summary
ABVC Quant Ranking